151 related articles for article (PubMed ID: 1997110)
1. Critical factors for the reversal of methotrexate cytotoxicity by folinic acid.
Bernard S; Etienne MC; Fischel JL; Formento P; Milano G
Br J Cancer; 1991 Feb; 63(2):303-7. PubMed ID: 1997110
[TBL] [Abstract][Full Text] [Related]
2. Leucovorin rescue of human cancer and bone marrow cells following edatrexate or methotrexate.
Jolivet J; Jansen G; Peters GJ; Pinard MF; Schornagel JH
Biochem Pharmacol; 1994 Feb; 47(4):659-65. PubMed ID: 7510479
[TBL] [Abstract][Full Text] [Related]
3. l-folinic acid versus d,l-folinic acid in rescue of high-dose methotrexate therapy in children.
Etienne MC; Thyss A; Bertrand Y; Touraine R; Rubie H; Robert A; Milano G
J Natl Cancer Inst; 1992 Aug; 84(15):1190-5. PubMed ID: 1635087
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of leucovorin reversal of methotrexate cytotoxicity in human MCF-7 breast cancer cells.
Boarman DM; Baram J; Allegra CJ
Biochem Pharmacol; 1990 Dec; 40(12):2651-60. PubMed ID: 2260989
[TBL] [Abstract][Full Text] [Related]
5. [l-folinic acid versus racemic folinic acid in the treatment of leukemia in children with high dose of methotrexate].
Etienne MC; Thyss A; Bertrand Y; Rubie H; Milano G
Bull Cancer; 1993 Apr; 80(4):357-63. PubMed ID: 8173189
[TBL] [Abstract][Full Text] [Related]
6. Methotrexate-induced cytotoxicity and genotoxicity in germ cells of mice: intervention of folic and folinic acid.
Padmanabhan S; Tripathi DN; Vikram A; Ramarao P; Jena GB
Mutat Res; 2009 Feb; 673(1):43-52. PubMed ID: 19110071
[TBL] [Abstract][Full Text] [Related]
7. Combination of reduced folates with methotrexate or 5-fluorouracil. Comparison between 5-formyltetrahydrofolate (folinic acid) and 5-methyltetrahydrofolate in vitro activities.
Etienne MC; Fischel JL; Formento P; Schneider M; Guillot T; Bardon M; Milano G
Biochem Pharmacol; 1993 Nov; 46(10):1767-74. PubMed ID: 8250962
[TBL] [Abstract][Full Text] [Related]
8. Reversal of methotrexate cytotoxicity to human bone marrow cells and leukemic K562 cells by leucovorin: methotrexate polyglutamates formation as a possible important factor.
Koizumi S; Ueno Y; Ohno I; Ichihara T; Tamaru Y; Matsukawa H
Jpn J Cancer Res; 1990 Nov; 81(11):1162-7. PubMed ID: 1702414
[TBL] [Abstract][Full Text] [Related]
9. Dose reduction without loss of efficacy for 5-fluorouracil and cisplatin combined with folinic acid. In vitro study on human head and neck carcinoma cell lines.
Etienne MC; Bernard S; Fischel JL; Formento P; Gioanni J; Santini J; Demard F; Schneider M; Milano G
Br J Cancer; 1991 Mar; 63(3):372-7. PubMed ID: 2003979
[TBL] [Abstract][Full Text] [Related]
10. High-dose methotrexate therapy with leucovorin rescue: in vitro investigations on human osteosarcoma cell lines.
Diddens H; Teufel T; Niethammer D
Cancer Chemother Pharmacol; 1987; 20(2):128-32. PubMed ID: 3499251
[TBL] [Abstract][Full Text] [Related]
11. Effects of leucovorin (folinic acid) in the methotrexate-treated rat brain.
Ogushi N; Sasaki K; Shimoda M
J Vet Med Sci; 2018 May; 80(5):760-765. PubMed ID: 29607891
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Cost-Effectiveness Between Actinomycin D Versus Methotrexate-Folinic Acid in the Treatment of Low-Risk Gestational Trophoblastic Neoplasia.
Lertkhachonsuk AA; Hanvoravongchai P
J Reprod Med; 2016; 61(5-6):230-4. PubMed ID: 27424364
[TBL] [Abstract][Full Text] [Related]
13. Treatment of low-risk gestational trophoblastic neoplasia comparing biweekly eight-day Methotrexate with folinic acid versus bolus-dose Actinomycin-D, among Brazilian women.
Uberti EM; Fajardo Mdo C; da Cunha AG; Frota SS; Braga A; Ayub AC
Rev Bras Ginecol Obstet; 2015 Jun; 37(6):258-65. PubMed ID: 26200823
[TBL] [Abstract][Full Text] [Related]
14. Large diversity in transport-mediated methotrexate resistance in human leukemia cell line CCRF-CEM established in a high concentration of leucovorin.
Asai S; Miyachi H; Kobayashi H; Takemura Y; Ando Y
Cancer Sci; 2003 Feb; 94(2):210-4. PubMed ID: 12708499
[TBL] [Abstract][Full Text] [Related]
15. Challenging the clinical relevance of folinic acid over rescue after high dose methotrexate (HDMTX).
Cohen IJ
Med Hypotheses; 2013 Nov; 81(5):942-7. PubMed ID: 24035689
[TBL] [Abstract][Full Text] [Related]
16. Weekly methotrexate (50mg/m(2)) without dose escalation as a primary regimen for low-risk gestational trophoblastic neoplasia.
Kang WD; Choi HS; Kim SM
Gynecol Oncol; 2010 Jun; 117(3):477-80. PubMed ID: 20347479
[TBL] [Abstract][Full Text] [Related]
17. Meningeal carcinomatosis in patients with breast carcinoma. Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen.
Fizazi K; Asselain B; Vincent-Salomon A; Jouve M; Dieras V; Palangie T; Beuzeboc P; Dorval T; Pouillart P
Cancer; 1996 Apr; 77(7):1315-23. PubMed ID: 8608509
[TBL] [Abstract][Full Text] [Related]
18. Schedule-dependent synergism and antagonism between raltitrexed ("Tomudex") and methotrexate in human colon cancer cell lines in vitro.
Kano Y; Akutsu M; Tsunoda S; Suzuki K; Yazawa Y; Furukawa Y
Jpn J Cancer Res; 2001 Jan; 92(1):74-82. PubMed ID: 11173547
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of methotrexate-induced chromosomal damage by folinic acid in V79 cells.
Keshava C; Keshava N; Whong WZ; Nath J; Ong TM
Mutat Res; 1998 Feb; 397(2):221-8. PubMed ID: 9541646
[TBL] [Abstract][Full Text] [Related]
20. Biochemical modulation of fluorouracil: comparison of methotrexate, folinic acid, and fluorouracil versus folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial.
Polyzos A; Tsavaris N; Giannopoulos A; Bacoyiannis C; Papadimas V; Kalahanis N; Karatzas G; Kosmas C; Sakelaropoulos N; Archimandritis A; Papachristodoulou A; Kosmidis P
Cancer Chemother Pharmacol; 1996; 38(3):292-7. PubMed ID: 8646806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
